SG11202106855YA - Gene therapy constructs for treating wilson disease - Google Patents

Gene therapy constructs for treating wilson disease

Info

Publication number
SG11202106855YA
SG11202106855YA SG11202106855YA SG11202106855YA SG11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA SG 11202106855Y A SG11202106855Y A SG 11202106855YA
Authority
SG
Singapore
Prior art keywords
gene therapy
wilson disease
therapy constructs
treating wilson
treating
Prior art date
Application number
SG11202106855YA
Other languages
English (en)
Inventor
Christine Livingston
Samuel Wadsworth
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of SG11202106855YA publication Critical patent/SG11202106855YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202106855YA 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease SG11202106855YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788324P 2019-01-04 2019-01-04
US201962834830P 2019-04-16 2019-04-16
PCT/US2020/012131 WO2020142653A1 (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Publications (1)

Publication Number Publication Date
SG11202106855YA true SG11202106855YA (en) 2021-07-29

Family

ID=69528954

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106855YA SG11202106855YA (en) 2019-01-04 2020-01-03 Gene therapy constructs for treating wilson disease

Country Status (19)

Country Link
US (1) US20220090131A1 (de)
EP (2) EP4269579A3 (de)
JP (2) JP2022516283A (de)
KR (1) KR20210112339A (de)
CN (1) CN113518628A (de)
AU (1) AU2020204679A1 (de)
BR (1) BR112021013140A2 (de)
CA (1) CA3124880A1 (de)
CO (1) CO2021010088A2 (de)
DK (1) DK3906066T3 (de)
ES (1) ES2970216T3 (de)
FI (1) FI3906066T3 (de)
HR (1) HRP20231750T1 (de)
IL (1) IL284554A (de)
MX (1) MX2021008135A (de)
PT (1) PT3906066T (de)
SG (1) SG11202106855YA (de)
TW (1) TW202043479A (de)
WO (1) WO2020142653A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3048044A1 (en) 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating wilson's disease
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
TW202102525A (zh) 2019-03-21 2021-01-16 美商史崔德生物公司 重組腺相關病毒載體
BR112021022951A2 (pt) * 2019-05-14 2022-01-25 Univ Duke Composições e métodos para o tratamento de doenças mediadas por atpase
TW202128736A (zh) 2019-10-17 2021-08-01 美商史崔德生物公司 用於治療c型尼曼—匹克病之腺相關病毒載體
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113694218A (zh) * 2021-08-30 2021-11-26 昆明理工大学 一种atp7b基因p992l突变的基因修复治疗载体
WO2023108130A2 (en) * 2021-12-10 2023-06-15 Aavantibio, Inc. Compositions comprising kozak sequences selected for enhanced expression
WO2023108159A1 (en) * 2021-12-10 2023-06-15 University Of Florida Research Foundation, Incorporated Methods and compositions for treating bag-3 related cardiomyopathy with a viral vector

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759050B1 (en) 1998-12-03 2004-07-06 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
ATE520707T1 (de) 2001-11-13 2011-09-15 Univ Pennsylvania Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen
EP2359869B1 (de) 2001-12-17 2018-12-26 The Trustees Of The University Of Pennsylvania Sequenzen von Adeno-assoziierte Viren (AAV) vom Serotyp 8, Vektoren enthaltend solche Sequenzen und Verwendungen dafür
SI2277996T1 (sl) 2003-05-21 2014-12-31 Genzyme Corporation Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid
EP2298926A1 (de) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Claden (Subtypen) und Sequenzen von Adeno-Assoziiertem Virus (AAV), diese enthaltende Vektoren und ihre Verwendungen
EP3409296A1 (de) 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
DK2242840T3 (da) 2008-01-29 2019-10-21 Applied Genetic Tech Corporation Produktion af rekombinant adeno-associeret virus under anvendelse af bhk-celler i suspension
US8679837B2 (en) 2009-04-02 2014-03-25 University Of Florida Research Foundation, Inc. Inducible system for highly efficient production of recombinant Adeno-associated virus (rAAV) vectors
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2529020B1 (de) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia Skalierbare herstellungsplattform zur reinigung von virenvektoren und gereinigte virenvektoren zur verwendung in gentherapien
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
MX2016014220A (es) * 2014-05-02 2017-02-06 Genzyme Corp Vectores de aav para la terapia genica de la retina y el snc.
ES2856090T3 (es) 2014-09-24 2021-09-27 Hope City Variantes de vectores de virus adenoasociados para la edición genómica de alta eficacia y sus métodos
IL252917B2 (en) * 2014-12-17 2023-10-01 Fundacion Para La Investig Medica Aplicada Vectors and vectors for gene therapy for use in the treatment of Wilson's disease
CA3048044A1 (en) * 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating wilson's disease
WO2023230466A1 (en) * 2022-05-23 2023-11-30 Lutsenka Svetlana Compositions and methods for treating wilson's disease

Also Published As

Publication number Publication date
HRP20231750T1 (hr) 2024-05-24
IL284554A (en) 2021-08-31
FI3906066T3 (fi) 2024-01-30
DK3906066T3 (da) 2024-02-05
CN113518628A (zh) 2021-10-19
ES2970216T3 (es) 2024-05-27
US20220090131A1 (en) 2022-03-24
WO2020142653A1 (en) 2020-07-09
EP4269579A3 (de) 2024-01-24
MX2021008135A (es) 2021-08-11
CA3124880A1 (en) 2020-07-09
EP3906066A1 (de) 2021-11-10
KR20210112339A (ko) 2021-09-14
JP2022516283A (ja) 2022-02-25
EP3906066B1 (de) 2023-11-01
EP4269579A2 (de) 2023-11-01
CO2021010088A2 (es) 2021-09-20
AU2020204679A1 (en) 2021-07-15
JP2024054426A (ja) 2024-04-16
TW202043479A (zh) 2020-12-01
PT3906066T (pt) 2024-02-06
BR112021013140A2 (pt) 2021-11-30

Similar Documents

Publication Publication Date Title
IL284554A (en) Structures for gene therapy to treat Wilson's disease
EP3562514A4 (de) Gentherapie zur behandlung der wilson-krankheit
IL277190A (en) Methods of treating HPV-related diseases
IL286825A (en) Gene therapy for eye pathologies
IL279918A (en) Gene therapy vectors for the treatment of Danon disease
EP3796891A4 (de) Therapeutische konstrukte zur behandlung von krebs
IL279685A (en) Gene therapy
IL285238A (en) Gene therapy vectors for the treatment of Danon disease
IL289667A (en) Cardiac aav gene therapy for cardiomyopathy in humans
GB202114972D0 (en) Gene therapy
EP3720509A4 (de) Globingentherapie zur behandlung von hämoglobinopathien
HK1253299A1 (zh) 一種通過基因治療治療眼疾病的改進方法
IL261292A (en) Gene therapy for the treatment of retinal degeneration
GB201522416D0 (en) Wilson's disease gene therapy
GB202003618D0 (en) Gene Therapy
GB201905301D0 (en) Gene therapy
IL276701A (en) Oligonucleotide therapy for Wilson's disease
IL306119A (en) Gene therapy for the treatment of beta-hemoglobinopathies
GB201802326D0 (en) Gene therapy
IL286099A (en) Methods of treating the disease using levoketoconazole
GB201817469D0 (en) Gene therapy for retinal disease
GB202003109D0 (en) Gene therapy
GB202002202D0 (en) Gene therapy
EP3781130A4 (de) Therapeutische konstrukte zur behandlung von krebs
EP3760209C0 (de) Spezifische gentherapie für ischämische läsionsstellen